# 10x Genomics, Inc. – Consensus ‘buy’ rating and 21.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc.consensus-buy-rating-and-21.0-upside-potential/4121135534
- Published: 2023-12-07T15:42:50+00:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** which can be found using ticker (TXG) now have 12 market 
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between $70.00 and $30.00 calculating the mean 
target price we have $54.83. Now with the previous closing price of $45.33 this 
would indicate that there is a potential upside of 21.0%. There is a 50 day moving
average of $40.13 and the 200 day moving average is $49.43. The company has a market
cap of 5.46B. The stock price for the company is currently $46.20 USD

 The potential market cap would be $6,605,794,153 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $5.09 and
a -12.15% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on:
